Research Tracker›Biomarker Atlas›Marker Pages›Anti-nuclear antibodies (ANA)

Anti-nuclear antibodies (ANA): biomarker evidence

Anti-nuclear antibodies (ANA) appears in 1 entry of the OSMF biomarker atlas, covering Gulf War Illness. Across those entries it is mixed in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

Gulf War Illness

Where Anti-nuclear antibodies (ANA) is reported

Also listed as: Autoimmune screen

ConditionDirectionCompared againstAssociated symptomsSource
Gulf War Illness↕ inconsistenthealthy Gulf War veteran controlsAutoimmune overlap subsetGean et al. 2021

Frequently asked questions

In which conditions is Anti-nuclear antibodies (ANA) altered?

In the OSMF atlas Anti-nuclear antibodies (ANA) is reported in Gulf War Illness. It is mixed in 1 across 1 entries.

Is there a standard clinical test for Anti-nuclear antibodies (ANA)?

The atlas entries for Anti-nuclear antibodies (ANA) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal Anti-nuclear antibodies (ANA) result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). Anti-nuclear antibodies (ANA) across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/anti-nuclear-antibodies-ana.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.